Cenduit Introduces New Clinical Trial Supply Simulation and Forecasting Service
News Dec 10, 2012
Cenduit LLC has introduced a new study simulation and forecasting service that will enable clinical trial sites to better plan and control supplies for their patients.
When integrated with Cenduit’s interactive response technology (IRT) services, the new service will give sponsors complete confidence in their clinical supply chain.
“Clinical trials are more complex than ever and a robust and reliable clinical trial supply strategy is vital to study success,” said Jogin Desai, Cenduit chief executive officer.
Desai continued, “The simulation and forecasting models, integrated with the patient randomization and drug allocation services inherent in our IRT systems, allow the complete coordination of procurement, packaging and logistics, with supply requirements from the sites themselves continuously factored in.”
Desai said the new system helps further minimize the risk of drug supply overage and drug outages at sites and accelerates drug development through increased supply chain productivity.
The system also allows clinical trial supply coordinators to test different supply scenarios before implementing them, and to identify in advance the risks associated with any supply strategy.
“By integrating forecasting and simulation parameters into the IRT system, patients will receive the right treatment on time, every time and at the lowest cost,” Desai said.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018